This article compares IGF-1 LR3 and IGF-1 DES across the dimensions that matter most in a research context: structure, receptor selectivity, IGFBP interactions, half-life, and practical protocol considerations
(PubMed) Holick MF, Matsuoka LY, Wortsman J
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles